Vagal Anti-Inflammatory Reflex >>
Autonomic Risk in the Morning >>
Modulation of Norepinephrine Release >>
Sympathetic Activity in Heart Failure >>
Parkinson's Disease, Etiology and Treatment >>
Cardiac Denervation in Parkinson's Disease >>
A PDF version of this Autonomic News can be downloaded from the CAR website
To review the original abstract of these articles, click on the references below
The
vagal anti-inflammatory reflex
Endotoxemia induces the
release of TNF-α
from macrophages, as part of an inflammatory process. Acetylcholine and
nicotine inhibit the release of TNF-α
from macrophages in vitro, through activation of nicotinic receptors. In
animals, vagal nerve stimulation inhibits the increase in plasma TNF-α induced
by endotoxemia in vivo (for review, see Tracey KJ. Nature
2002;420:853). It is proposed that acetylcholine diffuses from parasympathetic
nerve terminals in reticuloendothelial organs, to inhibit inflammatory cells.
Wang et al. studied the receptor subtype that mediates these actions.
Nicotinic acetylcholine receptors are a family of ligand-gated pentameric ion
channels. In humans, 16 different subunits have been identified (α1-7, α9-10,
β1-4, δ, ε, and γ), and pentameric receptors are formed by various combinations
of these subunits. It is known that the acetylcholine-sensitive TNF-α response
is blocked by α-bungarotoxin, a peptide antagonist that binds to
α1,
α7,
and α9.
Biding of α-bugarotoxin was present in human macrophages, and PCR confirmed the
expression of α1, α7 and α10 in these cells. Antisense oliogonucleotides
specific for α7 blunted the anti-TNF-α effects of nicotine in macrophages in
vitro. As expected, vagal nerve stimulation blunted the increase in TNF-α
induced by endotoxemia in normal mice, but this effect was blunted in
α7-deficient mice. These results suggest that the anti-inflammatory effects of
neurally-mediated acetylcholine are mediated by nicotinic receptors containing
the α7 subunit.
Wang H, Yu M, Ochani M et al.
(2003) Nicotinic acetylcholine receptor alpha7 subunit is an
essential regulator of inflammation.
421:384-388.
"Sometimes
it just doesn’t pay to get out of bed”
This is the conclusions Norman Kaplan reached in an editorial commenting
the article by Kario et al., which showed that early morning hypertension
was associated with strokes. Over 500 elderly with hypertension were studied
with ambulatory blood pressure monitoring. Over an average follow up of 41
months there were 44 strokes. Patients with the highest early morning blood
pressure (within 2 hours of arising) had a higher prevalence of multiple silent
infarcts at baseline MRI (57% versus 33%), and almost a three-fold higher stroke
incidence during follow up (19% versus 7.3%). It is believed that morning blood
pressure surge is mediated by autonomic mechanisms, and these results are in
agreement with the higher incidence of cardiovascular events reported early in
the morning.
Kario K, Pickering TG, Umeda Y et al. (2003) Morning Surge in
Blood Pressure as a Predictor of Silent and Clinical Cerebrovascular Disease in
Elderly Hypertensives: A Prospective Study. Circulation 107:1401-1406.
Modulation of norepinephrine release
Release of norepinephrine (NE) from sympathetic nerve terminals is
modulated by a number of factors acting on presynaptic receptors. To determine
if presynaptic histamine H3 receptors (H3R) inhibit NE
release Koyama et al. studied knock-out mice lacking H3R and
found that these mice had 60% high basal NE release than wild type mice. NE
exocytosis induced by K+-induced depolarization was attenuated by
adenosine and histamine agonists in wild type mice, but only by adenosine
agonists in H3R (-/-) mice. Ischemia-induced NE release was
inhibited 50% by H3R activation in wild type mice, but not in H3R
(-/-) mice. Thus, histamine receptors modulate NE release at rest, and during
physiological and pathological stimulation.
It is generally believed that presynaptic angiotensin II
receptors stimulate NE release from sympathetic terminals, although this remains
controversial (e.g., see Lameris, et al. Hypertension 2002;40:491).
Dendorfer at al., found that infusion of angiotensin II increased renal
sympathetic nerve traffic in pithed rats, even during ganglionic blockade, and
increased plasma norepinephrine 27-fold. These effects were blocked by an AT1
angiotensin receptor antagonist and by tetradotoxin. These results suggest a
direct effect of angiotensin II on autonomic ganglia, which can contribute to
the pressor effects of angiotensin II through sympathetic activation.
Koyama M, Seyedi N, Fung-Leung WP et al. (2003)
Norepinephrine release from the ischemic heart is greatly enhanced in mice
lacking histamine H3 receptors. Mol Pharmacol 63:378-382.
Dendorfer A, Thornagel A, Raasch W et al.
(2002) Angiotensin II induces catecholamine release by direct
ganglionic excitation. Hypertension 40:348-354.
Cardiac
sympathetic activity in congestive heart failure and autonomic disorders
Congestive heart
failure is associated with sympathetic activation, initially as a compensatory
mechanism, but detrimental in the long term. Aggarwal et al. performed a
proof-of-concept study in 10 patients with moderate-severe congestive heart
failure to examine potential beneficial effects of intravenous clonidine on
regional sympathetic activity. Clonidine preferentially reduced cardiac and
renal NE spillover (by 50 and 40%, respectively), compared to global NE
spillover (22% reduction). In addition to the beneficial effects of
antiadrenergic therapy in the heart, the renal sympatholytic effect may counter
the salt and water retention that is a hallmark of congestive heart failure.
Central sympatholitics should be further investigated for the treatment of this
condition.
Goldstein et al. used similar methodology to examine
cardiac NE spillover in patients with postural tachycardia syndrome (POTS) and
with neurocardiogenic syncope (NCS). Cardiac NE spillover was higher in POTS
(by about 68%) and lower in NCS (by about 40%) compared to healthy controls.
Despite differences in NE spillover, both patient groups had normal cardiac
extraction of NE, normal cardiac production of the intraneuronal NE metabolite
dihydroxyphenylalanine, and normal myocardial 6-[18F]fluorodopamine-derived
radioactivity, suggesting normal function of NE transporter and NE synthesis,
and normal density of myocardial sympathetic innervation.
Aggarwal A, Esler MD, Morris MJ et al.
(2003) Regional Sympathetic Effects of Low-Dose Clonidine in Heart
Failure. Hypertension 41:553-557.
Goldstein DS, Holmes C, Frank SM et al. (2002) Cardiac
sympathetic dysautonomia in chronic orthostatic intolerance syndromes.
Circulation 106:2358-2365.
Parkinson’s Disease, unusual causes and future treatments
Whereas only a small percentage of Parkinson disorders is monogenic,
such disorders can improve our understanding of general pathophysiological
mechanisms. Bonifati et al. described two consanguineous families from
genetically isolated communities in the Netherlands and Italy suffering from
autosomal recessive early-onset Parkinsonism. Homozygosity mapping localized
the responsible gene, labeled PARK7, on chromosome 1p36. Systematic PCR
screening of this region revealed mutations of the Dj-1 gene leading to loss of
function. This gene encodes a ubiquitous highly-conserved protein of unknown
function, but thought to be involved in the oxidative stress response. We will
need to wait for more studies to understand the role of this protein in
neurodegenerative disorders.
Brain
transplantation of dopamine-producing cells is theoretically appealing for the
treatment of Parkinson’s disease. This approach, however, has several
limitations. Transplants increase dopamine levels locally, but this effect is
usually transient and there is little restorative action on nigrostriatal
pathways. The source of transplanted cells and the need of immunosuppression
are also limiting factors. Toledo-Aral et al. studied the possible use
of carotid body cells as a source of transplants in a rat model of Parkinson’s
disease. Hemiparkinsonian rats were grafted intrastriatally with carotid body
cell aggregates. The motor syndrome improved in transplanted rats, apparently
as a result of the trophic actions of these grafts on the remaining ipsilateral
substantia nigra neurons, rather than of the release of dopamine. Remarkably,
grafts survived throughout the life of the animals. Improved survival of the
grafts was attributed to adult carotid body cells expressing high levels of glia
cell line-derived neurotrophic factor. Carotid body glomus cells, although
highly dopaminergic, are protected from dopamine-mediated oxidative damage
because they lack high-affinity dopamine transporters. Thus, carotid body cells
have theoretical advantages as a source of grafts to restore nigrostriatal
function.
Bonifati V, Rizzu P, van Baren MJ et al. (2003) Mutations in
the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.
299:256-259.;
Toledo-Aral JJ, Mendez-Ferrer S, Pardal R et al.
(2003) Trophic restoration of the
nigrostriatal dopaminergic pathway in long-term carotid body-grafted
parkinsonian rats. J Neurosci 23:141-148.
Cardiac denervation in Parkinson’s disease
Several imaging studies have now documented a high prevalence of
decreased uptake of catechols in the heart of patients with Parkinson’s disease,
suggesting decreased sympathetic innervation. Even among patients without
orthostatic hypotension, about half have diffusely decreased innervation. Li
et al. studied 9 such patients with repeat fluorodopamine scans taken on
average two years apart. They found that fluorodopamine cardiac uptake
decreased by about 30% in the second scan, compared to the initial one. This
findings suggest progressive cardiac denervation in Parkinson’s disease, even in
patients with no initial evidence of orthostatic hypotension.
Li ST, Dendi R, Holmes C et al.
(2002)
Progressive loss of cardiac sympathetic innervation in Parkinson's disease.
Ann Neurol 52:220-223.